A breakdown of the mission aiming to turn space into the next layer of digital infrastructure.
Updated
January 8, 2026 6:32 PM

The Hubble Space Telescope, one of the fist space infrastructures. PHOTO: UNSPLASH
PowerBank Corporation and Smartlink AI, the company behind Orbit AI, are preparing to send a very different kind of satellite into space. Their upcoming mission, scheduled for December 2025, aims to test what they call the world’s first “Orbital Cloud” — a system that moves parts of today’s digital infrastructure off the ground and into orbit. While satellites already handle GPS, TV signals and weather data, this project tries to do something bigger: turn space itself into a platform for computing, artificial intelligence (AI) and secure blockchain-based digital transactions. In essence, it marks the beginning of space-based cloud computing.
To understand why this matters, it is helpful to examine the limitations of our current systems. As AI tools grow more advanced, they require massive data centers that consume enormous amounts of electricity, especially for cooling. These facilities depend on national power grids, face regulatory constraints and are concentrated in just a few regions. Meanwhile, global connectivity still struggles with inequalities, censorship, congestion and geopolitical bottlenecks. The Orbital Cloud is meant to plug these gaps by building a computing and communication layer above Earth — a solar-powered, space-cooled network in Low Earth Orbit (LEO) that no single nation or company fully controls.
Orbit AI’s approach brings together two new systems. The first, called DeStarlink, is a decentralized satellite network designed for global internet-style connectivity and resilient communication. The second, DeStarAI, is a set of AI-focused in-orbit data centers placed directly on satellites, using space’s naturally cold environment instead of the energy-hungry cooling towers used on Earth. When these two ideas merge, the result is a floating digital layer where information can be transmitted, processed and verified without touching terrestrial infrastructure — a key shift in how AI workloads and cloud computing may be handled in the future.
PowerBank enters the picture by supplying the electricity and temperature-control technology needed to keep these satellites running. In space, sunlight is constant and uninterrupted — no clouds, no storms, no nighttime periods where panels lie idle. PowerBank plans to provide high-efficiency solar arrays and adaptive thermal systems that help the satellites manage heat in orbit. This collaboration marks a shift for PowerBank, which is expanding from traditional solar and battery projects into the realm of digital infrastructure, AI energy systems and next-generation satellite technology.
Describing the ambition behind this move, Dr. Richard Lu, CEO of PowerBank, said: “The next frontier of human innovation isn't just in space exploration, it's in building the infrastructure of tomorrow above the Earth”. He pointed to a future market that could surpass US$700 billion, driven by orbital satellites, AI computing in space, blockchain verification and solar-powered data systems. Integrating solar energy with orbital computing, he said, could help create “a globally sovereign, AI-enabled digital layer in space, which is a system that can help power finance, communications and critical infrastructure”.
Orbit AI’s Co-Founder and CEO, Gus Liu, describes their satellites as deliberately autonomous and intelligent. “Orbit AI is creating the first truly intelligent layer in orbit — satellites that compute, verify and optimize themselves autonomously”, he said, “The Orbital Cloud turns space into a platform for AI, blockchain and global connectivity. By leveraging solar-powered compute payloads and decentralized verification nodes, we are opening an entirely new, potentially US$700+ billion-dollar market opportunity — one that combines energy, data and sovereignty to reshape industries from finance to government and Web3. PowerBank's expertise in advanced solar energy systems will be significant in supporting this initiative."
This vision is not isolated. Earlier this year, Jeff Bezos echoed a similar idea at Italian Tech Week, saying: “We will be able to beat the cost of terrestrial data centres in space in the next couple of decades. These giant training clusters will be better built in space, because we have solar power there, 24/7 — no clouds, no rain, no weather. The next step is going to be data centres and then other kinds of manufacturing.” His comments reflect a growing industry belief that space-based data centers will eventually outperform those on Earth.
The idea gains traction because the advantages are practical. Space offers free, constant solar power. It provides natural cooling, which is one of the costliest parts of running data centers on Earth. And above all, satellites in low-Earth orbit operate beyond national firewalls and political boundaries, making them more resilient to outages, censorship and conflict. For industries that rely heavily on secure connectivity and real-time data — finance, defense, AI, blockchain networks and global cloud providers — this could become an important alternative layer of infrastructure.
The upcoming Genesis-1 satellite is designed as a demonstration mission. It will test an Ethereum wallet, run a blockchain verification node and perform simple AI tasks in orbit. If the technology works as expected, Orbit AI plans to add several more satellites in 2026, expand into larger networks by 2027 and 2028 and begin full commercial operations by the decade’s end.
To build this system, Orbit AI plans to source technologies from some of the world’s most influential players: NVIDIA for AI processors, the Ethereum Foundation for blockchain tools, Galaxy Space and SparkX Satellite for satellite components, Galactic Energy for launch systems and AscendX Aerospace for advanced materials.
If successful, the Orbital Cloud could become the first step toward a world where part of humanity’s data, computing power and digital services run not in massive buildings on Earth, but in clusters of autonomous satellites illuminated by constant sunlight. For now, the journey begins with a single launch — a test satellite aiming to show that space can do far more than connect us. It may soon help power the systems that run our economies, technologies and global communication networks.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM

HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.